 |
12 Diseases |  |
138 Trials |
|
138 Trials |  |
3994 News |  |
| «12...2829303132333435363738...3940» |
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk
New P2 trial: SEMPATICO: Semaglutide to Reduce Myocardial Injury in PATIents With COVID-19 (clinicaltrials.gov) - Nov 4, 2020
P2, N=400, Not yet recruiting, Sponsor: Vladimír Džavík
- [VIRTUAL] SAFETY AND EFFICACY OF COMBINATION THERAPIES INCLUDING SEMAGLUTIDE, CILOFEXOR, AND FIRSOCOSTAT IN PATIENTS WITH NASH () - Nov 2, 2020 - Abstract #AASLD2020AASLD_2144;
In patients with NASH, combinations of sema with CILO and/or FIR were well tolerated and may provide additional benefits vs sema monotherapy.
- | Byetta (exenatide) / AstraZeneca, semaglutide SC once-daily (NN9536) / Novo Nordisk
Retrospective data, Journal: Indirect comparison of glucagon like peptide-1 receptor agonists regarding cardiovascular safety and mortality in patients with type 2 diabetes mellitus: network meta-analysis. (Pubmed Central) - Oct 28, 2020
The indirect comparison and ranking probability results have shown that one weekly semaglutide and oral semaglutide seems to be the preferred option in patients with T2DM and established or at high risk of CVD. This result can aid health care providers, pharmacy and therapeutics committees in hospitals, and insurance companies when deciding which GLP1RA to start or add to their formulary.
- || Ozempic (semaglutide SC once-weekly) / Novo Nordisk
@novonordisk Is this amount of packaging really necessary? Each package contains a single Ozempic injector pen, 6 single-use needles and about a metric tonne of paperwork and packaging materials. #DoBetter (Twitter) - Oct 22, 2020
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk, Trulicity (dulaglutide) / Eli Lilly
Journal: A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release, Dulaglutide and Liraglutide in the UK. (Pubmed Central) - Oct 21, 2020
The present study showed that once-weekly semaglutide offers superior cost of control versus exenatide ER, dulaglutide and liraglutide in terms of achieving clinically relevant, single and composite endpoints. Once-weekly semaglutide 1 mg would therefore represent good value for money in the UK setting.
- |||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Trial completion date, Trial primary completion date: FOCUS: A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes (clinicaltrials.gov) - Oct 19, 2020
P3, N=1500, Recruiting, Sponsor: Novo Nordisk A/S
Once-weekly semaglutide 1 mg would therefore represent good value for money in the UK setting. Trial completion date: Feb 2026 --> Aug 2026 | Trial primary completion date: Jan 2026 --> Jul 2026
- |||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Enrollment open: STRIDE: A Research Study to Compare a Medicine Called Semaglutide Against Placebo in People With Peripheral Arterial Disease and Type 2 Diabetes (clinicaltrials.gov) - Oct 19, 2020
P3, N=800, Recruiting, Sponsor: Novo Nordisk A/S
Trial completion date: Feb 2026 --> Aug 2026 | Trial primary completion date: Jan 2026 --> Jul 2026 Not yet recruiting --> Recruiting
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk
@novonordisk Your Ozempic commercial is nauseating and maybe worse than the Liberty Mutual commercials. I wouldn't take Ozempic if you payed me. (Twitter) - Oct 12, 2020
- Ozempic (semaglutide SC once-weekly) / Novo Nordisk, semaglutide SC once-daily (NN9536) / Novo Nordisk
[VIRTUAL] Reduction in the Rate of eGFR Decline with Semaglutide vs. Placebo: A Post Hoc Pooled Analysis of SUSTAIN 6 and PIONEER 6 (Simulive) - Oct 11, 2020 - Abstract #KIDNEYWEEK2020KIDNEY_WEEK_3629;
Semaglutide was associated with a significantly smaller decline in kidney function than PBO in subjects with T2D at high CV risk across tested BL eGFR categories; the data suggest the main benefit might be observed in those with kidney disease. Funding: Commercial Support
- Ozempic (semaglutide SC once-weekly) / Novo Nordisk, semaglutide SC once-daily (NN9536) / Novo Nordisk
[VIRTUAL] Hemoglobin A1c Reduction with the GLP-1 Receptor Agonist Semaglutide Is independent of Baseline eGFR: Post Hoc Analysis of SUSTAIN and PIONEER Programs (On-Demand) - Oct 11, 2020 - Abstract #KIDNEYWEEK2020KIDNEY_WEEK_1805;
Semaglutide (subcutaneous and oral) is an effective glucose-lowering agent in subjects with T2D, independently of baseline eGFR, including in those with chronic kidney disease. Funding: Commercial Support
- Ozempic (semaglutide SC once-weekly) / Novo Nordisk, semaglutide SC once-daily (NN9536) / Novo Nordisk
[VIRTUAL] Effects of Semaglutide on CKD Outcomes: A Post Hoc Pooled Analysis from the SUSTAIN 6 and PIONEER 6 Trials (On-Demand) - Oct 11, 2020 - Abstract #KIDNEYWEEK2020KIDNEY_WEEK_1799;
This analysis of semaglutide CVOTs supports the possibility of a smaller magnitude of eGFR decline with semaglutide vs PBO and suggests a potential kidney disease benefit of semaglutide vs PBO in people with T2D and established CKD. Funding: Commercial Support
- Ozempic (semaglutide SC once-weekly) / Novo Nordisk, semaglutide SC once-daily (NN9536) / Novo Nordisk
[VIRTUAL] AKI Associated with Semaglutide (On-Demand) - Oct 11, 2020 - Abstract #KIDNEYWEEK2020KIDNEY_WEEK_1782;
To our knowledge, Patient 1 is the first reported case with biopsy findings. Patients developing new symptoms after starting semaglutide should have laboratory tests performed and the drug discontinued if there is worsening renal function.
- ||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Trial completion: A Research Study Looking at the Comparability (Bioequivalence) of Two Forms of Semaglutide in Two Different Pen-injectors in People With Overweight or Obesity (clinicaltrials.gov) - Oct 8, 2020
P1, N=68, Completed, Sponsor: Novo Nordisk A/S
Patients developing new symptoms after starting semaglutide should have laboratory tests performed and the drug discontinued if there is worsening renal function. Active, not recruiting --> Completed
- ||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Trial completion, Real-world evidence, Real-world: A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in United Kingdom, as Part of Local Clinical Practice (SURE UK) (clinicaltrials.gov) - Oct 7, 2020
P=N/A, N=221, Completed, Sponsor: Novo Nordisk A/S
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Enrollment open: Study of Semaglutide for Non-Alcoholic Fatty Liver Disease (NAFLD), a Metabolic Syndrome With Insulin Resistance, Increased Hepatic Lipids, and Increased Cardiovascular Disease Risk (The SLIM LIVER Study) (clinicaltrials.gov) - Oct 7, 2020
P2, N=50, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- || Mounjaro (tirzepatide) / Eli Lilly
Enrollment closed: A Study of Tirzepatide in Participants With Type 2 Diabetes Mellitus (T2DM) (clinicaltrials.gov) - Oct 5, 2020
P1, N=117, Active, not recruiting, Sponsor: Eli Lilly and Company
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- [VIRTUAL] EFFECTS OF SEMAGLUTIDE VS COMPARATORS ON CARDIOVASCULAR EVENTS ACROSS A CONTINUUM OF BASELINE CARDIOVASCULAR RISK: COMBINED ANALYSIS OF THE SUSTAIN AND PIONEER TRIALS (Inxpo Platform, Simulive + Text Q&A) - Oct 4, 2020 - Abstract #CCCCanada2020CCC_Canada_90;
Fewer major adverse cardiovascular events (MACE) were observed with semaglutide vs placebo in cardiovascular outcomes trials (CVOTs) in subjects with type 2 diabetes (T2D) at high risk of cardiovascular (CV) events (once-weekly subcutaneous semaglutide in SUSTAIN 6; once-daily oral semaglutide in PIONEER 6). To better understand the CV effect of semaglutide in a broader range of subjects with T2D, including those at lower CV risk, we conducted a post hoc analysis of semaglutide and comparator (placebo, sitagliptin, exenatide extended release, insulin glargine, dulaglutide, liraglutide, and empagliflozin) data from all phase 3a SUSTAIN and PIONEER trials across the continuum of baseline CV risk characterizing a broad T2D population.
- metformin / Generic mfg., Ozempic (semaglutide SC once-weekly) / Novo Nordisk, Jardiance (empagliflozin) / Eli Lilly, Boehringer Ingelheim
[VIRTUAL] Evaluating the Cost-Effectiveness of Once-Weekly Semaglutide 1 MG Versus Empagliflozin 25 MG for Treatment of Patients with Type 2 Diabetes in the UK Setting () - Oct 3, 2020 - Abstract #ISPOREU2020ISPOR-EU_1738;
Once-weekly semaglutide was associated with a mean increase in costs of GBP 1,017, leading to an incremental cost-effectiveness ratio of GBP 4,439 per QALY gained. CONCLUSIONS Once-weekly semaglutide 1 mg is likely to be a cost-effective treatment from a healthcare payer perspective compared with empagliflozin 25 mg for the treatment of patients with type 2 diabetes in the UK setting.
- metformin / Generic mfg., Ozempic (semaglutide SC once-weekly) / Novo Nordisk, Jardiance (empagliflozin) / Eli Lilly, Boehringer Ingelheim
[VIRTUAL] LONG-TERM Cost-Effectiveness Analyses of Once-Weekly Semaglutide 1 MG Versus Empagliflozin 25 MG for Treatment of Type 2 Diabetes in Three Countries- Bosnia and Herzegovina, Greece, and Slovenia () - Oct 3, 2020 - Abstract #ISPOREU2020ISPOR-EU_1660;
RESULTS Over patient lifetimes, once-weekly semaglutide 1 mg was associated with quality-adjusted life expectancy increases versus empagliflozin 25 mg of 0.19, 0.21, and 0.21 quality-adjusted life years (QALYs) in Bosnia and Herzegovina, Greece, and Slovenia, respectively.In Greece, cost savings due to avoided complications entirely offset increased pharmacy costs, with once-weekly semaglutide associated with cost savings of EUR 1,767.In Bosnia and Herzegovina and Slovenia, increased pharmacy costs were only partially offset by avoided complication costs, with once-weekly semaglutide associated with mean cost increases of EUR 853 and EUR 880, respectively.Once-weekly semaglutide was considered dominant versus empagliflozin in Greece, and was associated with incremental cost-effectiveness ratios of EUR 4,397 and EUR 4,122 per QALY gained in Bosnia and Herzegovina and Slovenia, respectively. CONCLUSIONS In Bosnia and Herzegovina, Greece, and Slovenia, once-weekly semaglutide is likely to be to be a cost-effective therapy from a healthcare payer perspective compared with empagliflozin 25 mg for the treatment of patients with type 2 diabetes.
- metformin / Generic mfg., Ozempic (semaglutide SC once-weekly) / Novo Nordisk, Jardiance (empagliflozin) / Eli Lilly, Boehringer Ingelheim
[VIRTUAL] A LONG-TERM Cost-Effectiveness Analysis of Treatments for Type 2 Diabetes in Portugal- Once-Weekly Semaglutide 1 MG Versus Once-Daily Empagliflozin 25 MG () - Oct 3, 2020 - Abstract #ISPOREU2020ISPOR-EU_1583;
RESULTS Over patient lifetimes, once-weekly semaglutide 1 mg was associated with increased life expectancy (12.80 versus 12.70 years) and quality-adjusted life expectancy (7.18 versus 6.98 quality-adjusted life years [QALYs]) compared with once-daily empagliflozin 25 mg.The benefits resulted from a reduced incidence and delayed onset of diabetes-related complications.Cost savings resulting from avoided diabetes-related complications partially offset increased pharmacy costs with once-weekly semaglutide, leading to an overall cost increase of EUR 2,804 (EUR 24,845 versus EUR 22,041).Once-weekly semaglutide was associated with an incremental cost-effectiveness ratio of EUR 14,114 per QALY gained versus once-daily empagliflozin. CONCLUSIONS Compared with once-daily empagliflozin 25 mg, once-weekly semaglutide 1 mg was projected to be a cost-effective treatment from a healthcare payer perspective for patients with type 2 diabetes in Portugal.
- Ozempic (semaglutide SC once-weekly) / Novo Nordisk
[VIRTUAL] MODEL-Based LONG-TERM Cost-Effectiveness of Once-Weekly Semaglutide Compared with Other GLP-1 Receptor Agonists in Type 2 Diabetes- A Systematic Literature Review () - Oct 3, 2020 - Abstract #ISPOREU2020ISPOR-EU_131;
Results based on the IQVIA Core diabetes model and IHE model were similar. The treatment algorithm and criteria for treatment change assumed in the model simulation would be more important for the long-term projection than the economic model used.CONCLUSIONS :The current literature presents that compared with dulaglutide and other GLP-1 RAs, once-weekly semaglutide was considered dominated or highly cost-effectiveness treatment alternative for type 2 diabetes.
- Rybelsus (semaglutide oral) / Novo Nordisk, Ozempic (semaglutide SC once-weekly) / Novo Nordisk
[VIRTUAL] The Cost-Effectiveness of ORAL Semaglutide in Patients Treated with Currently Available GLP-1 Receptor Agonists - a UK Perspective () - Oct 3, 2020 - Abstract #ISPOREU2020ISPOR-EU_66;
The comparison provided here is relevant to payers, as it demonstrates what they are currently paying versus the new oral formulation. Physician and patient preference is important when selecting which GLP-1RA to prescribe for a patient.
- | Victoza (liraglutide) / Novo Nordisk, Rybelsus (semaglutide oral) / Novo Nordisk, Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Retrospective data, Journal: Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials. (Pubmed Central) - Oct 3, 2020
P3
Semaglutide reduced the risk of MACE vs comparators across the continuum of baseline CV risk in a broad T2D population. Trial registrations ClinicalTrials.gov identifiers: NCT02054897, NCT01930188, NCT01885208, NCT02128932, NCT02305381, NCT01720446, NCT02207374, NCT02254291, NCT02906930, NCT02863328, NCT02607865, NCT02863419, NCT02827708, NCT02692716, NCT02849080, NCT03021187, NCT03018028, NCT03015220.
- |||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
New trial: Epidemiological Assessment of the Risk for Pancreatic Cancer Associated With the Use of Semaglutide in Patients With Type 2 Diabetes - A Cohort Study Based on Nordic Registry Data (clinicaltrials.gov) - Sep 30, 2020
P, N=200000, Not yet recruiting, Sponsor: Novo Nordisk A/S
- |||| cotadutide (MEDI0382) / AstraZeneca
Enrollment open: A Study of Cotadutide in Participants Who Have Chronic Kidney Disease With Type 2 Diabetes Mellitus (clinicaltrials.gov) - Sep 28, 2020
P2b, N=225, Recruiting, Sponsor: AstraZeneca
Trial registrations ClinicalTrials.gov identifiers: NCT02054897, NCT01930188, NCT01885208, NCT02128932, NCT02305381, NCT01720446, NCT02207374, NCT02254291, NCT02906930, NCT02863328, NCT02607865, NCT02863419, NCT02827708, NCT02692716, NCT02849080, NCT03021187, NCT03018028, NCT03015220. Not yet recruiting --> Recruiting
- || Clinical, Retrospective data, Journal: Efficacy and safety of semaglutide for type 2 diabetes by race and ethnicity: a post hoc analysis of the SUSTAIN trials. (Pubmed Central) - Sep 26, 2020
Semaglutide 0.5 or 1.0 mg, placebo, or active comparator (sitagliptin 100 mg, exenatide extended release 2.0 mg, insulin glargine 100IU/ml and dulaglutide 0.75 or 1.5 mg)...The most commonly reported AEs were gastrointestinal disorders. s): In this SUSTAIN trials post hoc analysis, semaglutide was associated with consistent and clinically relevant reductions in HbA1c and body weight in subjects with T2D, with minor variations in efficacy and safety outcomes associated with race or ethnicity.
- |||||||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
New P3 trial: STRIDE: A Research Study to Compare a Medicine Called Semaglutide Against Placebo in People With Peripheral Arterial Disease and Type 2 Diabetes (clinicaltrials.gov) - Sep 22, 2020
P3, N=800, Not yet recruiting, Sponsor: Novo Nordisk A/S
- ||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Not surprising results, Semaglutide 2.4mg once weekly reduces appetite and food cravings. #EASD2020 (Twitter) - Sep 22, 2020
- | Review, Journal: Type 2 diabetes and the kidney: insights from cardiovascular outcome trials. (Pubmed Central) - Sep 19, 2020
Despite some residual limitations linked to differences in study populations and patient characteristics, the cardiorenal protective actions of SGLT-2 inhibitors, and to a lesser extent by some GLP-1 agonists, make them favorable medications for patients with T2D at increased cardiorenal risk. There is room for optimism that their use may change the paradigm of the ineluctable progression of DKD.
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk, semaglutide SC once-daily (NN9536) / Novo Nordisk
Journal: Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5. (Pubmed Central) - Sep 18, 2020
P3
The STEP program evaluates the efficacy and safety of semaglutide 2.4 mg subcutaneously once weekly in a broad population. The trials will provide insights on WM in people with obesity with and without type 2 diabetes and on long-term follow-up.
- Ozempic (semaglutide SC once-weekly) / Novo Nordisk, semaglutide SC once-daily (NN9536) / Novo Nordisk
[VIRTUAL] Semaglutide Reduces Mace Consistently Across Baseline Triglyceride Levels in Patients With Type 2 Diabetes: A Post Hoc Analysis of the Sustain 6 and Pioneer 6 Trials (OnDemand) - Sep 17, 2020 - Abstract #AHA2020AHA_2952;
P3
In this post hoc analysis of SUSTAIN 6 and PIONEER 6, over half of patients had elevated TG levels (>151 mg/dL). Semaglutide consistently reduced the risk of MACE vs placebo across baseline TG levels.
- || Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Clinical, Journal: Improved treatment satisfaction in patients with type 2 diabetes treated with once-weekly semaglutide in the SUSTAIN trials. (Pubmed Central) - Sep 9, 2020
P3
Semaglutide was associated with significantly greater (SUSTAIN 2-5) or similar (SUSTAIN 7) improvements in overall treatment satisfaction versus comparators/placebo. Improvements in overall treatment satisfaction were generally greater in patients achieving versus not achieving treatment targets.
- || Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Enrollment closed, Real-world evidence, Real-world: A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Germany, as Part of Local Clinical Practice (SURE GERMANY) (clinicaltrials.gov) - Sep 7, 2020
P=N/A, N=730, Active, not recruiting, Sponsor: Novo Nordisk A/S
Improvements in overall treatment satisfaction were generally greater in patients achieving versus not achieving treatment targets. Enrolling by invitation --> Active, not recruiting
- || Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Enrollment closed: A Research Study to Compare Two Different Forms of Once-weekly Semaglutide in Two Different Injection Pens (clinicaltrials.gov) - Sep 3, 2020
P1, N=111, Active, not recruiting, Sponsor: Novo Nordisk A/S
Enrolling by invitation --> Active, not recruiting Recruiting --> Active, not recruiting
- |||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
New P4 trial: TRANSITION-T2D: Transition From Basal/Bolus to Once-weekly Subcutaneous Semaglutide and Basal Insulin in Patients With Type-2 Diabetes Mellitus (clinicaltrials.gov) - Sep 3, 2020
P4, N=100, Not yet recruiting, Sponsor: The Cleveland Clinic
- || Ozempic (semaglutide SC once-weekly) / Novo Nordisk, Trulicity (dulaglutide) / Eli Lilly
Clinical, Journal, HEOR: Lower Drug Cost of Successfully Treating Patients with Type 2 Diabetes to Targets with Once-Weekly Semaglutide versus Once-weekly Dulaglutide in Japan: A Short-Term Cost-Effectiveness Analysis. (Pubmed Central) - Sep 2, 2020
These findings suggest that once-weekly semaglutide is a cost-effective treatment option compared with once-weekly dulaglutide for patients with T2D in Japan. In the future, this finding should be extrapolated to traditional long-term cost-effectiveness analysis, using common outcomes such as quality-adjusted life years.
- ||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Enrollment closed, Trial completion date: STEP 1: Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity (clinicaltrials.gov) - Aug 26, 2020
P3, N=1964, Active, not recruiting, Sponsor: Novo Nordisk A/S
In the future, this finding should be extrapolated to traditional long-term cost-effectiveness analysis, using common outcomes such as quality-adjusted life years. Completed --> Active, not recruiting | Trial completion date: Apr 2020 --> Feb 2021
- || okay, I know U R a busy man. My diet meds now: 1- Contrave 2- Ozempic 3- Invokana 4- Metformin 5- Coffee 6- Alcohol (Twitter) - Aug 25, 2020
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk, Jardiance (empagliflozin) / Eli Lilly, Boehringer Ingelheim, Trulicity (dulaglutide) / Eli Lilly
Don’t forget Trulicity, Ozempic, Jardiance, Invokanna and all the combinations of them. (Twitter) - Aug 22, 2020
- || Ozempic (semaglutide SC once-weekly) / Novo Nordisk
@NashTagConf @novonordiskus #Ozempic shots the only help in 70 years of obesity lost now 50 lbs over 3 yrs (Twitter) - Aug 22, 2020
- |||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Enrollment closed: A Research Study on How Well Semaglutide Works in Adolescents With Overweight or Obesity (clinicaltrials.gov) - Aug 19, 2020
P3, N=163, Active, not recruiting, Sponsor: Novo Nordisk A/S
Completed --> Active, not recruiting | Trial completion date: Apr 2020 --> Feb 2021 Recruiting --> Active, not recruiting
- |||||| cotadutide (MEDI0382) / AstraZeneca
New P2b trial: A Study of Cotadutide in Participants Who Have Chronic Kidney Disease With Type 2 Diabetes Mellitus (clinicaltrials.gov) - Aug 16, 2020
P2b, N=237, Not yet recruiting, Sponsor: AstraZeneca
- || Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Que viene a Honduras 🇭🇳 ? pues ya pronto semaglutide Ozempic @novonordisk aGlp1 semanal importante reducción de peso aún comparado con otro aGlp1 (Twitter) - Aug 8, 2020
- ||| Firsocostat (GS-0976) / Gilead, cilofexor (GS-9674) / Gilead
Trial completion, Monotherapy: Safety, Tolerability, and Efficacy of Monotherapy and Combination Regimens in Participants With Nonalcoholic Steatohepatitis (NASH) (clinicaltrials.gov) - Aug 8, 2020
P2, N=109, Completed, Sponsor: Gilead Sciences
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- || Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Trial completion date, Trial primary completion date: A Research Study of How Semaglutide Works in People With Disease Affecting the Heart and/or Blood Vessels and Type 2 Diabetes (clinicaltrials.gov) - Aug 7, 2020
P1, N=100, Recruiting, Sponsor: Novo Nordisk A/S
Active, not recruiting --> Completed Trial completion date: Sep 2021 --> Dec 2021 | Trial primary completion date: May 2020 --> May 2021
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Trial completion date, Trial primary completion date: Study of Semaglutide for Non-Alcoholic Fatty Liver Disease (NAFLD), a Metabolic Syndrome With Insulin Resistance, Increased Hepatic Lipids, and Increased Cardiovascular Disease Risk (The SLIM LIVER Study) (clinicaltrials.gov) - Aug 7, 2020
P2, N=50, Not yet recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Trial completion date: Sep 2021 --> Dec 2021 | Trial primary completion date: May 2020 --> May 2021 Trial completion date: Jan 2022 --> May 2022 | Trial primary completion date: Aug 2021 --> Dec 2021
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Hej! Ska Ozempic lindra sötsug? (Twitter) - Jul 30, 2020
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk, Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca
Retrospective data, Journal: Comparative efficacy of once-weekly semaglutide versus SGLT-2 inhibitors in patients inadequately controlled with one to two oral antidiabetic drugs: a systematic literature review and network meta-analysis. (Pubmed Central) - Jul 25, 2020
Trial completion date: Jan 2022 --> May 2022 | Trial primary completion date: Aug 2021 --> Dec 2021 Once-weekly semaglutide demonstrated statistically significant and clinically meaningful reductions in HbA1c and body weight in T2D patients inadequately controlled with 1-2 OADs compared to all SGLT-2is licensed in Europe and North America.
- ||| Rybelsus (semaglutide oral) / Novo Nordisk, Ozempic (semaglutide SC once-weekly) / Novo Nordisk, Trulicity (dulaglutide) / Eli Lilly
Clinical, P3 data, Clinical Trial,Phase III, Journal: Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): an open-label, randomised, active-controlled, phase 3a trial. (Pubmed Central) - Jul 19, 2020
P3
Oral semaglutide was well tolerated in Japanese patients with type 2 diabetes. Once-daily oral semaglutide significantly reduced HbA (14 mg dose) and bodyweight (7 mg and 14 mg doses) versus weekly subcutaneous dulaglutide 0·75 mg by week 52.
- Ozempic (semaglutide SC once-weekly) / Novo Nordisk
[VIRTUAL] Addressing the needs of patients beyond glycaemic control: effects of once-weekly semaglutide (Vienna Hall) - Jul 2, 2020 - Abstract #EASD2020EASD_1466;